Why Cannabis Deals Stall After Signing (and How to Actually Get to Closing)

Most cannabis deals don’t fail—they stall after signing. Learn the key execution risks around approvals, disclosures, and consents that determine whether your deal actually closes.

---

Most deals don’t die — they stall.

In cannabis transactions, signing the purchase agreement is not the finish line. It’s the beginning of the most fragile phase of the deal: execution. This is where timelines slip, approvals drag, issues surface, and momentum disappears. And once a deal stalls, it rarely recovers without cost — whether through renegotiation, delay, or complete collapse.

The difference between deals that close and deals that stall is not negotiation. It’s execution strategy.

1. Approval Timing Misalignment

One of the most common execution failures is misunderstanding how long regulatory approvals actually take and failing to build that reality into the deal.

Cannabis transactions often require:

• State-level approval for ownership changes

• Local approvals or notifications

• Background checks and disclosures

• Supplemental information requests from regulators

  
  

These processes do not operate on deal timelines. They operate on agency timelines.

Common mistakes:

• Setting overly optimistic closing dates without aligning them to realistic approval timelines.

• Outside dates that trigger termination before approvals are realistically obtainable.

• No affirmative obligation for parties to actively pursue change-of-ownership and control approvals.

Business impact:

• Missed closing deadlines

• Forced re-trades or economic concessions

• Repeated extension negotiations

• Capital tied up longer than expected

• Increased risk of deal fatigue or collapse

  
  

What strong operators do:

They structure timelines around regulatory reality — not optimism. That means:

• Building in realistic approval windows (with buffer)

• Tying outside dates to regulatory progress, not arbitrary timelines

• Requiring both sides to actively prosecute approvals

• Aligning economic risk with delay (e.g., extensions, ticking fees, or staged consideration)

  
  

Execution isn’t about hoping the process works. It’s about engineering the deal so it can.

2. Incomplete Ownership Disclosures

Ownership disclosure is not a formality in cannabis. It is one of the most heavily scrutinized aspects of any transaction, making it the most common source of delay.

Regulators typically require disclosure of:

• Direct and indirect owners

• Passive investors

• Lenders and financial interest holders

• Individuals with control or influence
  

Even small inconsistencies or omissions can trigger:

• Follow-up inquiries

• Restarted review periods

• Requests for additional documentation

  
  

Where deals break:

Failing to fully vet and map ownership and financial interests before submitting applications.

Business impact:

• Approval delays and extended review cycles

• Increased regulatory scrutiny across the deal

• Potential restructuring requirements or outright denial

  
  

What strong operators do:

They treat ownership disclosure as a core diligence workstream, not a checklist item. That means:

• Building a complete ownership and control map early

• Reconciling equity, debt, and contractual control rights

• Confirming ownership and control compliance before submission

• Aligning legal structure with how regulators assess “control” in practice

  
  

In cannabis, regulators don’t just ask who owns the business — they ask who actually controls it.

3. Third-Party Consent Failures

Most cannabis deals don’t exist in isolation. They depend on third-party relationships, and those relationships often include consent rights that can block or delay closing.

Key examples:

• Landlords - lease assignment or change-of-control consent

• Lenders - restrictions on ownership changes or transfers

• Vendors and partners - contractual approval or termination rights

  
  

These provisions are often buried in underlying agreements and overlooked until late in the process.

Where deals break:

Identifying consent requirements too late or assuming they will be granted without issue.

Business impact:

• Delayed closings while consents are negotiated

• Renegotiated deal economics to satisfy third parties

• Inability to close if consent is withheld or conditioned

  
  

What strong operators do:

They identify and address all third-party consent requirements early. That means:

• Auditing all material contracts before signing

• Identifying consent and assignment restrictions upfront

• Engaging third parties early—before the deal is locked

• Structuring closing conditions around required consents

• Building fallback paths where consent risk is high

Execution risk isn't just regulatory. It's contractual.

Practical Takeaways

• Build deal timelines around real regulatory approval periods, not target closings

• Complete ownership and financial interest mapping before filing applications

• Audit all contracts for consent, assignment, and change-of-control restrictions

• Treat execution as an active process, not a passive waiting period

• Align all stakeholders around a clear, realistic path to closing

Cannabis Deal-Specific Execution Realities

Execution risk is amplified in cannabis because regulators and counterparties both scrutinize control, structure, and compliance.

• Ownership vs. Control: Regulators assess actual control (including governance rights, vetoes, and economic influence) not just equity ownership.

• License Caps: Transactions must be structured to avoid exceeding ownership limits across jurisdictions.

• Disclosure Sensitivity: Passive investors, lenders, and minority holders may still trigger disclosure and approval requirements.

• Approval Timing Variability: Timelines differ significantly across states and municipalities — and are often unpredictable.

• Third-Party Friction: Landlords, lenders, and counterparties are more risk-sensitive in cannabis, making early alignment essential.

  
  

Conclusion

Deals don’t fail because they were poorly negotiated. They fail because execution wasn’t engineered.

If you want a deal to close, a signed agreement isn’t enough. You need a structure—and a plan—that accounts for regulators, third parties, and real-world timing.

Greenbar works with operators and investors to structure and execute transactions that don’t stall—they close.